ReviewBMC pediatrics2026
Cosegregation of congenital dysferlinopathy phenotype and marinesco-sjögren syndrome: a case report with literature review.
Review in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The congenital dysferlinopathy phenotype is the rarest and earliest manifestation variant, described in two closely related Spanish and Turkish families, with a homozygous pathogenic frameshift variant in exon 26 of the DYSF gene.This article presents a 1.6-year-old patient from a consanguineous Uzbek family with a clinical diagnosis of congenital dysferlinopathy phenotype and Marinesco–Sjögren syndrome with transient postnatal hypotonia, motor development delay, muscle weakness in the flexors of the neck and proximal limbs, convergent strabismus, cerebellar truncal ataxia, minimal intention tremor of the upper limbs, a slight increase in the levels of creatinine phosphokinase (CK) to 353 U/L (2.4×N) and that of myoglobin to 40 µg/mL (2×N).Magnetic resonance imaging (MRI) revealed pronounced edematous changes in the gastrocnemius muscle on short tau inversion recovery (STIR). MRI signs of minimal fat replacement and hypotrophy were noted in the medial and posterior thigh and gastrocnemius muscles. MRI of the head revealed hypoplasia of the vermis and cerebellar hemispheres. Whole-exome sequencing revealed compound heterozygous DYSF variants: NM_001130987.2:c.1000 C > T (p.(Arg334Trp)) and NM_001130987.2:c.518 C > T (p.(Thr173Met)), and a previously described homozygous SIL1 variant NM_022464.5:c.178G > T (p.(Glu60Ter)). Histopathological examination revealed minimal signs of myopathy and dysferlin in only 1% of the muscle fibers. At the ultrastructural level, signs of dysferlinopathy and Marinesco–Sjögren syndrome were detected.This clinical case is an example of the cosegregation of two diseases that mutually potentiate damage to skeletal muscles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.